Kaleido Biosciences Inc (KLDO PINK) stock market data APIs
$0
0(0%)
as of July 9, 2025
Try our APIs with
free plan!
Kaleido Biosciences Inc Financial Data Overview
Price chart is built with
Anychart
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of multi drug resistant infection, chronic kidney disease, atherosclerotic cardiovascular disease, cardio-metabolic syndrome, immuno-oncology, and inflammatory bowel diseases. The company has collaboration agreements with Institute Gustave Roussy, Washington University, and Janssen. Kaleido Biosciences, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Prev. Close
0
Open
0
High
0
Low
0
52 wk Range
0-0.07
Market Cap
4 262
Shares Outstanding
42 623 K
Revenue
1 104 K
EPS
0
Beta
20.684
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Kaleido Biosciences Inc data using free add-ons & libraries
Get Kaleido Biosciences Inc Fundamental Data
Kaleido Biosciences Inc Fundamental data includes:
- Net Revenue: 1 104 K
- EBITDA: -85 164 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2022-08-10
- EPS/Forecast: -0.25
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Kaleido Biosciences Inc News
New
Exelixis (EXEL) Initiates Early Stage Study of Lymphoma
Exelixis, Inc. EXEL recently announced that it has initiated the dose-escalation stage of the first-in-human phase I study of investigational candidate XL114. XL114 is a novel anti-cancer compound th...
Kaleido Biosciences Investor Alert: Kaplan Fox Investigates Potential Securities Fraud at Kaleido Biosciences, Inc.
NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Kaleido Biosciences, Inc. (“Kaleido Biosciences” or...
Kaleido Biosciences Shares Plunging To 52-Week Low, Read Why
Kaleido Biosciences Inc (NASDAQ: KLDO) has delivered formal notice to voluntarily delist its common stock from NASDAQ as the Company will stop all operations. The Company expects to file a Form 25 wit...
Novartis (NVS) Beovu Gets Label Expansion for DME in EU
Novartis NVS recently announced that the European Commission (“EC”) has approved a label expansion of its ophthalmology drug Beovu (brolucizumab). The EC approved Beovu for the treatment of visua...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
